Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the XARELTO boxed warnings and is directly supported by the provided label excerpts, with no contradictions or material omissions for the specific statements made.
Category Scores
Accurate Statements
Premature discontinuation of XARELTO increases the risk of thrombotic events.
Supported by BOXED WARNING (A) and Section 5.1: “Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events.” and “Premature discontinuation... in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.”
Epidural/spinal hematomas have occurred in patients treated with XARELTO receiving neuraxial anesthesia or undergoing spinal puncture.
Supported by BOXED WARNING (B): “Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture.”
These hematomas may result in long-term or permanent paralysis.
Supported by BOXED WARNING (B) and corroborated by Section 5.3: BOXED WARNING (B) states “may result in long-term or permanent paralysis,” and Section 5.3 states the same risk characterization.
Unsupported Statements
Contradictions
Important Omissions
The boxed warning text includes additional operational details (e.g., consider coverage with another anticoagulant when discontinued for reasons other than pathological bleeding or completion of therapy; and neuraxial procedure risk factors/monitoring guidance).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The AI statements precisely reflect the core boxed warning risks described in the provided label excerpts. No missing critical safety elements were required to support the specific claims made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
If expanding beyond the core claim, include the label’s boxed-warning conditional guidance (e.g., consideration of alternative anticoagulation) and the neuraxial anesthesia management/monitoring details from the label.